RET fusions were firstly identified in lung cancer in 2012 (12), and MKIs such as cabozantinib (3), lenvatinib (4), and vandetanib (5) were available with limited responses and high rates of off-target toxicities. This evidence concerns the gene RET and lung carcinoma.